• Home
  •  / Pandion Therapeutics

Pandion Therapeutics

OverviewSuggest Edit

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. The Company is aimed to create a new generation of drugs with transformative efficacy and safety.

TypePrivate
Founded2017
HQCambridge, MA, USMap
Websitepandiontx.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Apr 2021)66(+5%)
Cybersecurity ratingCMore

Key People/Management at Pandion Therapeutics

Alan Crane

Alan Crane

Director
Nancy Stagliano

Nancy Stagliano

Independent Director
Jo Viney

Jo Viney

President, Chief Scientific Officer and Co-Founder
Don Frail

Don Frail

Independent Director
Vikas Goyal

Vikas Goyal

Senior Vice President, Business Development
John S. Sundy

John S. Sundy

Chief Medical Officer
Show more

Pandion Therapeutics Office Locations

Pandion Therapeutics has offices in Cambridge and Watertown
Cambridge, MA, US (HQ)
610 Main St
Watertown, MA, US
134 Coolidge Ave 2nd floor
Show all (2)

Pandion Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Pandion Therapeutics total Funding

$138 m

Pandion Therapeutics latest funding size

$80 m

Time since last funding

a year ago

Pandion Therapeutics investors

Polaris Partners, Versant Ventures, SR One, Roche Venture Fund, Boxer Capital, OrbiMed, JDRF T1D Fund, BioInnovation, BioInnovation Capital, RA Capital, Access Biotechnology
Pandion Therapeutics's latest funding round in April 2020 was reported to be $80 m. In total, Pandion Therapeutics has raised $138 m
Show all financial metrics

Pandion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Pandion Therapeutics Online and Social Media Presence

Pandion Therapeutics's Trends

Embed Graph

Pandion Therapeutics News and Updates

February 27, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Pandion Therapeutics, Inc. - PAND

NEW YORK, Feb. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
February 25, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout

WILMINGTON, Del., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Pandion Therapeutics, Inc. (“Pandion”) (NASDAQ GS: PAND) regarding possible breaches of fiduciary duties and other violations of law related to Forterra’s agreement to be acquired by Merck &a…
February 22, 2021

Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the Compan…
February 18, 2021

Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Execut…
January 04, 2021

Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases-PT101 maintained selectivity for regulatory T …
December 03, 2020

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D…
Show more

Pandion Therapeutics Blogs

October 28, 2020

The Power Within: Bifunctional Antibodies Enable Local Tissue Targeting

Despite the many challenges presented by the COVID-19 pandemic, our team at Pandion – like many in the biotechnology sector . . . The post <strong>The Power Within:</strong> Bifunctional Antibodies Enable Local Tissue Targeting appeared first on Pandion Therapeutics.

 Pandion Therapeutics Frequently Asked Questions

  • When was Pandion Therapeutics founded?

    Pandion Therapeutics was founded in 2017.

  • Who are Pandion Therapeutics key executives?

    Pandion Therapeutics's key executives are Alan Crane, Nancy Stagliano and Jo Viney.

  • How many employees does Pandion Therapeutics have?

    Pandion Therapeutics has 66 employees.

  • Who are Pandion Therapeutics competitors?

    Competitors of Pandion Therapeutics include ImCheck Therapeutics, Praxis Precision Medicines and CBR International.

  • Where is Pandion Therapeutics headquarters?

    Pandion Therapeutics headquarters is located at 610 Main St, Cambridge.

  • Where are Pandion Therapeutics offices?

    Pandion Therapeutics has offices in Cambridge and Watertown.

  • How many offices does Pandion Therapeutics have?

    Pandion Therapeutics has 2 offices.